Advances in Lymphoma
Transcript: The landscape of lymphoma treatment
Professor Wojciech Jurczak
Interview recorded April 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
The era of chemo, or chemoimmunotherapy, is ending. We have the largest practice with chemoimmunotherapeutic regimens. The whole perspective is changing. The chemotherapy as such is evolving to targeted chemotherapy.
We are not yet ready to use the molecular targeted approaches in high-grade lymphomas. We are, however, ready to use modern immunotherapy and it is of great importance that patients refractory to the first two lines of chemo, refractory to the high dose chemo of autologous transplants have a chance, and the modern immunotherapy may offer them a realistic chance of cure.
The more compounds we have, the better we can treat and cure patients relapsing/refractory to the first line. But it is the first line where we win most of the battles.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event